Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received February 19, 2014
- Revision received March 17, 2014
- Accepted March 18, 2014
- Published online April 28, 2014.
Copyright & Usage
Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
Author Information
- 1Department of Obstetrics out Gynecology, Division of Reproductive Endocrinology and Infertility, Cooper Medical School of Rowan University, Camden, NJ, U.S.A.
- 2Cooper Institute For Reproductive Hormonal Disorders, P.C., Marlton, NJ, U.S.A.
- 3Department of Obstetrics and Gynecology, Philadelphia College of Osteopathic Medicine, Philadelphia, PA, U.S.A.
- Correspondence to: Jerome H. Check, MD, Ph.D., 7447 Old York Road, Melrose Park, PA 19027, U.S.A. Tel: +1 2156354156, Fax: +1 2156352304, e-mail: laurie{at}ccivf.com
Cited By...
In this issue
Evidence that Mifepristone, a Progesterone Receptor Antagonist, Can Cross the Blood Brain Barrier and Provide Palliative Benefits for Glioblastoma Multiforme Grade IV
Jump to section
Related Articles
Cited By...
- Palliative Benefits of Oral Mifepristone for the Treatment of Metastatic Fibroblastic Osteosarcoma
- Treatment With Mifepristone Allows a Patient With End-stage Pancreatic Cancer in Hospice on a Morphine Drip to Restore a Decent Quality of Life
- Therapy Aimed to Suppress the Production of the Immunosuppressive Protein Progesterone Induced Blocking Factor (PIBF) May Provide Palliation and/or Increased Longevity for Patients With a Variety of Different Advanced Cancers - A Review
- Mifepristone Extends Both Length and Quality of Life in a Patient With Advanced Non-small Cell Lung Cancer that Has Progressed Despite Chemotherapy and a Check-point Inhibitor
- Long-term High-quality Survival with Single-agent Mifepristone Treatment Despite Advanced Cancer